Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology

PRESS RELEASE

More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology

Frankfurt am Main, April 15, 2025 – More Impact AG (ISIN: DE000A1PG979, “More Impact”), a listed high-tech medical hub, announces that its subsidiary BG Braingate Technology GmbH (“Braingate Technology”) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another of its technological innovations.

This means that the issuance of the patent by the US authorities is binding and absured. An important milestone for the international marketing of products based on the patented device and a special extraction process has thus been reached.

The patent application relates to an innovative device and a method for the efficient, selective and gentle extraction of one or more components from biological materials, in particular cannabinoids such as the medically used CBD. The biological components obtained by the patented process can be processed accordingly and administered either via the medical inhaler or via the needleless syringe, depending on the medical indication.

Dr. Karsten Behlke, Managing Director of BG Braingate Technology: “The pending issuance of the US patent is an important milestone for our international protection strategy and the commercial exploitation of our technology in the fast-growing market for plant-based active substances.”

Dr. Gerald Schüssel, CEO of More Impact: “With the US patent granted in the near future, the high level of technological innovation in our portfolio companies is once again underpinned on an international scale.”

With the forthcoming patent grant, More Impact and Braingate Technology are expanding their leading technological position in the field of innovative extraction processes.

The forthcoming patent issuance complements the existing patent families and underpins the high-tech medical hub's claim to technological and innovative leadership.

About More Impact AG
More Impact AG is a listed high-tech medical hub that specializes in the development and support of innovative companies in the medical field. With a focus on securing patents and commercializing product innovations, More Impact contributes to making cutting-edge MedTech technologies accessible to a broad part of the population and sustainably improving global healthcare. Strategic acquisitions and divestitures of companies, divisions or individual patents round off the business model.

Contact – Investor & Media Relations
edicto GmbH
Axel Mühlhaus / Svenja Liebig
+49 69 90550 5-50
moreimpact@edicto.de